Treatment of Hyponatremia with Tolvaptan in a Patient after Neurosurgical Treatment of a Pituitary Tumor: Case Report and Review of Literature

Abstract

Hyponatremia is a frequent complication following pituitary surgery. We report a case with hyponatremia after surgery of a pituitary adenoma that was successfully treated with tolvaptan. A 68-year-old man with a pituitary tumor presented with mild hyponatremia (133 mEq/L) before surgery. The patient developed hyponatremia (125 mEq) 4 days postsurgery, and 10% sodium chloride was infused. Seven 7 days postsurgery, hyponatremia was improved (132 mEq/L), and tolvaptan 15 mg was given orally as a single dose instead of the 10% sodium chloride infusion. His serum sodium remained within normal limits. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) after pituitary surgery most probably led to the hyponatremia, and tolvaptan was effective because it is an oral vasopressin receptor antagonist.

Keywords

hyponatremia - pituitary tumor - tolvaptan

• References

• 1 Jahangiri A, Wagner J, Tran MT , et al. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations. J Neurosurg 2013; 119 (6) 1478-1483
• 2 Buckley MS, Patel SA, Hattrup AE, Kazem NH, Jacobs SC, Culver MA. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults. Ann Pharmacother 2013; 47 (9) 1194-1200
• 3 Janneck M, Burkhardt T, Rotermund R, Sauer N, Flitsch J, Aberle J. Hyponatremia after trans-sphenoidal surgery. Minerva Endocrinol 2014; 39 (1) 27-31
• 4 Nathan BR. Cerebral correlates of hyponatremia. Neurocrit Care 2007; 6 (1) 72-78
• 5 Guerrero R, Pumar A, Soto A , et al. Early hyponatraemia after pituitary surgery: cerebral salt-wasting syndrome. Eur J Endocrinol 2007; 156 (6) 611-616
• 6 Kelly DF, Laws Jr ER, Fossett D. Delayed hyponatremia after transsphenoidal surgery for pituitary adenoma. Report of nine cases. J Neurosurg 1995; 83 (2) 363-367
• 7 Olson BR, Gumowski J, Rubino D, Oldfield EH. Pathophysiology of hyponatremia after transsphenoidal pituitary surgery. J Neurosurg 1997; 87 (4) 499-507
• 8 Hannon MJ, Thompson CJ. Neurosurgical hyponatremia. J Clin Med 2014; 3 (4) 1084-1104
• 9 Sterns R, Hix J. Hyponatremia: vasopressin antagonists in hyponatremia: more data needed. Nat Rev Nephrol 2011; 7 (3) 132-133
• 10 Fraser JF, Stieg PE. Hyponatremia in the neurosurgical patient: epidemiology, pathophysiology, diagnosis, and management. Neurosurgery 2006; 59 (2) 222-229 ; discussion 222–229
• 11 Sherlock M, O'Sullivan E, Agha A , et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J 2009; 85 (1002) 171-175
• 12 Berl T, Quittnat-Pelletier F, Verbalis JG , et al; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21 (4) 705-712
• 13 Schrier RW, Gross P, Gheorghiade M , et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355 (20) 2099-2112
• 14 Verbalis JG, Goldsmith SR, Greenberg A , et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013; 126 (10) (Suppl. 01) S1-S42